Mass Spectrometry in Chronic Kidney Disease Research

Advances in Chronic Kidney Disease

Volumn 17, Issue 6, 2010, Pages 455-468

  Merchant, Michael L ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Peptidome; Plasma; Proteome; Serum; Targeted proteomics; Urine

Indexed keywords

BIOLOGICAL MARKER; PEPTIDOME; PROTEOME; UNCLASSIFIED DRUG;

ACCURACY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; HUMAN; ISOTOPE LABELING; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PLASMA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SERUM; URINE;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PROTEINS; RENAL INSUFFICIENCY, CHRONIC;

EID: 78049449702     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.09.003     Document Type: Review

References (55)

1. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266.
2. Abboud H., Henrich W.L. Clinical practice. Stage IV chronic kidney disease. N Engl J Med 2010, 362:56-65.
3. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
4. System USRD USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
5. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
6. Eddy A.A., Neilson E.G. Chronic kidney disease progression. J Am Soc Nephrol 2006, 17:2964-2966.
7. Zhang X., Fang A., Riley C.P., et al. Multi-dimensional liquid chromatography in proteomics-A review. Anal Chim Acta 2010, 664:101-113.
8. Yates J.R., Ruse C.I., Nakorchevsky A. Proteomics by mass spectrometry: Approaches, advances, and applications. Annu Rev Biomed Eng 2009, 11:49-79.
9. Agron I.A., Avtonomov D.M., Kononikhin A.S., et al. Accurate mass tag retention time database for urine proteome analysis by chromatography-Mass spectrometry. Biochemistry (Mosc) 2010, 75:636-641.
10. Brenton AG, Godfrey AR: Accurate mass measurement: Terminology and treatment of data. J Am Soc Mass Spectrom (in press).
11. Qian W.J., Liu T., Monroe M.E., et al. Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: The human proteome. J Proteome Res 2005, 4:53-62.
12. Pan C., Kumar C., Bohl S., et al. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics 2009, 8:443-450.
13. Ong S.E., Blagoev B., Kratchmarova I., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
14. Chalkley R.J., Hansen K.C., Baldwin M.A. Bioinformatic methods to exploit mass spectrometric data for proteomic applications. Methods Enzymol 2005, 402:289-312.
15. Grigoryev Y.A., Kurian S.M., Nakorchevskiy A.A., et al. Genome-wide analysis of immune activation in human T and B cells reveals distinct classes of alternatively spliced genes. PLoS One 2009, 4:e7906.
16. Kurian S.M., Heilman R., Mondala T.S., et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009, 4:e6212.
17. Nakorchevsky A., Hewel J.A., Kurian S.M., et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010, 21:362-373.
18. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
19. Merchant M.L., Perkins B.A., Boratyn G.M., et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009, 20:2065-2074.
20. Good DM, Zurbig P, Argiles A, et al: Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (in press).
21. Rossing K., Mischak H., Dakna M., et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008, 19:1283-1290.
22. Coon J.J., Zurbig P., Dakna M., et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008, 2:964.
23. Siuzdak G. The emergence of mass spectrometry in biochemical research. Proc Natl Acad Sci U S A 1994, 91:11290-11297.
24. Makarov A., Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J Chromatogr A 2010, 1217:3938-3945.
25. Xu Y., Heilier J.F., Madalinski G., et al. Evaluation of accurate mass and relative isotopic abundance measurements in the LTQ-orbitrap mass spectrometer for further metabolomics database building. Anal Chem 2010, 82:5490-5501.
26. Fenn J.B., Mann M., Meng C.K., et al. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246:64-71.
27. Hillenkamp F., Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol 1990, 193:280-295.
28. Mann M., Kelleher N.L. Precision proteomics: The case for high resolution and high mass accuracy. Proc Natl Acad Sci U S A 2008, 105:18132-18138.
29. Creese A.J., Cooper H.J. Liquid chromatography electron capture dissociation tandem mass spectrometry (LC-ECD-MS/MS) versus liquid chromatography collision-induced dissociation tandem mass spectrometry (LC-CID-MS/MS) for the identification of proteins. J Am Soc Mass Spectrom 2007, 18:891-897.
30. Cooper H.J., Hakansson K., Marshall A.G. The role of electron capture dissociation in biomolecular analysis. Mass Spectrom Rev 2005, 24:201-222.
31. Zubarev R.A. Electron-capture dissociation tandem mass spectrometry. Curr Opin Biotechnol 2004, 15:12-16.
32. Palmblad M., Tsybin Y.O., Ramstrom M., et al. Liquid chromatography and electron-capture dissociation in Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 2002, 16:988-992.
33. Hakansson K., Emmett M.R., Hendrickson C.L., et al. High-sensitivity electron capture dissociation tandem FTICR mass spectrometry of microelectrosprayed peptides. Anal Chem 2001, 73:3605-3610.
34. Wenger C.D., McAlister G.C., Xia Q., et al. Sub-part-per-million precursor and product mass accuracy for high-throughput proteomics on an electron transfer dissociation-enabled orbitrap mass spectrometer. Mol Cell Proteomics 2010, 9:754-763.
35. McAlister G.C., Berggren W.T., Griep-Raming J., et al. A proteomics grade electron transfer dissociation-enabled hybrid linear ion trap-orbitrap mass spectrometer. J Proteome Res 2008, 7:3127-3136.
36. Williams D.K., McAlister G.C., Good D.M., et al. Dual electrospray ion source for electron-transfer dissociation on a hybrid linear ion trap-orbitrap mass spectrometer. Anal Chem 2007, 79:7916-7919.
37. McAlister G.C., Phanstiel D., Good D.M., et al. Implementation of electron-transfer dissociation on a hybrid linear ion trap-orbitrap mass spectrometer. Anal Chem 2007, 79:3525-3534.
38. Wiese S., Reidegeld K.A., Meyer H.E., et al. Protein labeling by iTRAQ: A new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7:340-350.
39. Old W.M., Meyer-Arendt K., veline-Wolf L., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4:1487-1502.
40. Link A.J., Eng J., Schieltz D.M., et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999, 17:676-682.
41. Yates J.R., Link A.J., Schieltz D. Direct analysis of proteins in mixtures. Application to protein complexes. Methods Mol Biol 2000, 146:17-26.
42. Lopez M.F., Rezai T., Sarracino D.A., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010, 56:281-290.
43. Picotti P., Bodenmiller B., Mueller L.N., et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138:795-806.
44. Addona T.A., Abbatiello S.E., Schilling B., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.
45. Meier-Kriesche H.U., Ojo A.O., Port F.K., et al. Survival improvement among patients with end-stage renal disease: Trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001, 12:1293-1296.
46. Paul L.C. Chronic allograft nephropathy: An update. Kidney Int 1999, 56:783-793.
47. Mengel M., Sis B., Halloran P.F. SWOT analysis of Banff: Strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. Am J Transplant 2007, 7:2221-2226.
48. Cosio F.G., Grande J.P., Larson T.S., et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005, 5:1130-1136.
49. Wolters D.A., Washburn M.P., Yates J.R. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001, 73:5683-5690.
50. Systems URD USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2007, National Institutes of Health, NIoDaDaKD, Bethesda, MD.
51. Bauer C., Melamed M.L., Hostetter T.H. Staging of chronic kidney disease: Time for a course correction. J Am Soc Nephrol 2008, 19:844-846.
52. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
53. Kolch W., Neususs C., Pelzing M., et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005, 24:959-977.
54. Zurbig P., Decramer S., Dakna M., et al. The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 2009, 9:2108-2117.
55. Mueller L.N., Brusniak M.Y., Mani D.R., et al. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res 2008, 7:51-61.